Roivant Sciences Ltd. (ROIV)
| Market Cap | 7.87B |
| Revenue (ttm) | 29.05M |
| Net Income (ttm) | -171.98M |
| Shares Out | 679.81M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,065,590 |
| Open | 11.27 |
| Previous Close | 11.22 |
| Day's Range | 11.19 - 11.58 |
| 52-Week Range | 8.73 - 13.06 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 17.50 (+51.25%) |
| Earnings Date | Aug 7, 2025 |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monocl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ROIV stock is "Buy." The 12-month stock price target is $17.5, which is an increase of 51.25% from the latest price.
News
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1...
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik...
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2025, an...
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, Ma...
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's Fc...
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D.
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid ...
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger ...
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a ...
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatme...
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics Zest is initially focused on treating the millions ...
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, Feb...
Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development
WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision medicine for autoimmune diseases, and Roivant, a global biopharmaceutical company that aims to improve the lives of patients by...
Roivant Sciences: A Biotech Growth Play With Major Ambitions
Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT...
Roivant's lung disease drug fails mid-stage trial
Roivant said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of lung disease.
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimm...
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, No...
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant ha...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
BASEL, Switzerland and LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-clas...